Expanding the reach of pre-exposure prophylaxis services in suburban and rural Ontario: an implementation science evaluation of a public health-led model Authors: Carmela Rapino, Emma Nagy, Sahar Saeed, Beatriz Alvarado, Nicole Szumlanski, Miriam Kamotho, T. Hugh Guan, Jorge Martinez-Cajas Published: 2026 ABSTRACT BackgroundDespite the proven efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV, disparities among service delivery prevail in Canada, particularly among suburban and rural regions. This study evaluates the reach and effectiveness of a mixed-service delivery PrEP clinic embedded within a public health unit, located in Southeastern Ontario.MethodsThe PrEP clinic possesses an interdisciplinary team that delivers in-person and remote services. In consultation with PrEP clinic staff, we used the RE-AIM Framework to describe client characteristics (reach) and evaluate implementation effectiveness across the continuum of care, leveraging client electronic medical records.ResultsBetween 2018 and 2024, 141 clients engaged in PrEP services, the majority of whom were cisgender men (97.2%) with a median age of 37 years. Of those assessed, 70% (n = 98) initiated PrEP. Initiation was more likely among clients living outside the catchment area (RR = 1.35, 95% CI: 1.11–1.64), those with a history of hepatitis B (RR = 1.45, 95% CI: 1.30–1.62), and those reporting a history of having an HIV-positive partner (RR = 1.33, 95% CI: 1.18–1.49). The median duration of engagement was 8 months (IQR: 3–21 months), with no new HIV diagnoses reported. Overall, 54.1% of clients disengaged (n = 53), with the highest rates occurring within the first 3 months and after 12 months. Common reasons for disengagement included transferring care (24.5%), moving (18.9%), and changes in sexual activity (16.98%).ConclusionThis evaluation demonstrates that mixed-service public-health led PrEP delivery models can effectively engage clients in suburban and rural settings. Findings support the scalability of flexible, public health led approaches to expanding equitable access to PrEP in Canada.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-025-25205-7. Introduction Human Immunodeficiency Virus (HIV) is on the rise in Canada, with a 35.2% increase in new diagnoses from 2022–2023 [1]. Pre-exposure Prophylaxis (PrEP) is a highly effective HIV prevention strategy that remains underutilized [2], with the recent surge in new cases highlighting persistent gaps in implementation and equitable service delivery [3]. In Canada, healthcare delivery, including drug coverage, is managed at the provincial and territorial level [4]. As a results, access to PrEP and associated costs vary across province and territory. In British Columbia, Saskatchewan, Alberta, Manitoba, Prince Edward Island, and the territories, eligible individuals can receive PrEP through publicly funded programs [5]. In contrast, Ontario and Quebec do not provide publicly funded PrEP [6]. In Quebec, publicly funded coverage is limited to specific groups such as those under 18 years of age, full-time students under 25 years of age without a spouse or living with parents, and those with a functional impairment or receiving social assistance [6]. Residents who do not meet these criteria are required to pay up to $93.08 per month (approximately $1,117 per year) [6]. In Ontario, coverage is available through the Ontario Health Insurance Plan (OHIP) for those < 25 years old or for those ≥ 65 qualifying with Ontario Disability Support Programme, Ontario Works, or those under the Trillium Drug Program [6]. For Ontarians who do not qualify for coverage, PrEP can cost approximately $250 per month [6]. These differences in coverage across provinces help explain observed variability in uptake, affordability, and geographic equity in PrEP provision [6]. On the service level, PrEP in Canada was initially delivered through centralized, specialist-led or hospital-based models [7]. To enhance scalability, decentralized models have emerged [8]. While primary care providers (PCPs) have the purview to provide PrEP services, low adoption and ongoing shortages have provoked task-shifting to other health care professionals [8, 9]. In Ottawa, Ontario, and Victoria, British Columbia, nurse-led models delivered in public health settings that utilize medical directives have demonstrated effective reductions in HIV seroconversion and strong retention [9, 10]. Furthermore, community-based organizations, such as the Health Initiative for Men in Vancouver, British Columbia [11], and sexual health clinics, such as La Clinique Médicale l'Actuel in Montréal, Quebec [12], have also been recognised as critical resources for PrEP services as they both leverage their unique expertise’s, such as in queer-specific messaging and in sexual health, respectively, while notably implementing simple service delivery models. In addition, Nova Scotia is piloting pharmacist-led PrEP-prescribing services and while pharmacists have demonstrated strong acceptability, there have been concerns raised regarding the potential increased burden of work and perceived sexual health knowledge [13, 14]. To mitigate some barriers, digital health services, such as Go Freddie, offer discrete and convenient PrEP services online, however, these services may not be suitable for individuals requiring in-person routine consultations to optimize retention and adherence [15]. Despite these efforts to diversify service delivery models, PrEP uptake in Canada remains low relative to epidemiological need. Notable disparities exist between provinces, with the highest incidence rates reported in Saskatchewan and Manitoba [1]. Furthermore, intra-provincial disparities exist. In Ontario, 75% of all individuals receiving PrEP resided in the two most populated cities in the province, Ottawa and Toronto [16]. This distribution underscores the limited availability of PrEP services in suburban and rural regions, and, to our knowledge, no evaluations have been published examining service delivery outside major metropolitan centers across Canada. In addition to inter- and intra-provincial variability, there are key populations, such as Black and Indigenous Peoples, who are disproportionately affected by inequitable access to PrEP services due to intersecting factors such as PCP attachment, health insurance, financial barriers, rurality, newcomer status, and anti-Black and anti-Indigenous racism [17–19]. In response to these ongoing gaps, in 2018, Kingston, Frontenac, Lennox, and Addington Public Health (KFL&A PH) established a PrEP clinic. We will refer to this clinic as “The PrEP Clinic” for the remainder of this article. We sought out to describe client characteristics among initiation status, assess predictors of PrEP initiation, and describe rates of adherence, sexually transmitted and bloodborne infections (STBBIs), disengagement, and reasons for disengagement. Methods Implementation science evaluation This analysis is part of a larger mixed-methods evaluation designed to examine all domains of the RE-AIM framework—Reach, Effectiveness, Adoption, Implementation, and Maintenance—and inform strategies for integrating PrEP into public health settings across Ontario. The RE-AIM framework was selected because of its pragmatic orientation, flexible application, and wide use in implementation science to evaluate real-world health interventions across public health [20, 21]. This framework was particularly well-suited to our study as it allowed us to assess individual-level outcomes while also examining real-world effectiveness outcomes [20]. The broader project combined quantitative and qualitative methods, including client surveys, qualitative interviews with PCPs, PrEP clients, and clinic staff, and stakeholder discussions to identify barriers, facilitators, and implementation strategies (Supplemental Table 1). For this manuscript, we focused on the quantitative component of the evaluation, using a retrospective cohort design based on routinely collected data from electronic medical record (EMR) chart review of clients enrolled in the PrEP clinic between November 2018 and December 2024. A few implementation-related indicators were included to provide additional context for interpreting the findings. This approach allowed us to quantitatively assess clinic reach and effectiveness—two domains of particular interest to primary care providers seeking to understand the extent and impact of PrEP service delivery. Reach assesses the extent to which PrEP services engage the target population, including the proportion and representativeness of individuals who receive or are affected by the provision of the PrEP Clinic, while Effectiveness evaluates the clinics effect on health outcomes (HIV, STBBI incidence) and any unintended consequences (adverse effects) [12]. Other RE-AIM dimensions, along with qualitative findings from the broader evaluation (e.g., staff perspectives and fidelity assessment), will be reported in a separate manuscript. The PrEP clinic: history and mixed-service delivery model The PrEP clinic was developed by KFL&A PH in 2018 to address persistent geographical disparities in HIV prevention and growing community need. Prior to its implementation, there were no decentralized or out-of-hospital services providing PrEP services in this region. At the time of the study, the health unit served over 205,000 residents across a mixed suburban and rural area in Southeastern Ontario, covering 1,938.92 km2 [22, 23]. Importantly, the PrEP clinic remains the only dedicated service providing comprehensive HIV prevention care, including PrEP prescriptions and monitoring, between the mid-sized city of Peterborough to the nation’s capital, Ottawa, Ontario, a corridor covering over 20,000 km2 – highlighting its critical role in addressing geographical disparities in access [24]. Of note, in January 2025, KFL&A PH has since merged with two neighbourhood public health units, forming SEPH. The findings presented here reflect the PrEP clinic run by the legacy KFL&A PH agency and the catchment area it serves. The PrEP Clinic is one of the services delivered by the health units Sexual Health Program (SHP), which is operated by an interdisciplinary team including a manager, program assistant, a clinical nursing facilitator, two data clerks, six nurses, a public health and preventive medicine physician, and rotating medical residents. At clinic inception (November 2018), PrEP clients were seen in person by a nurse and physician, and testing was completed on-site. In October 2020, service delivery shifted due to the COVID-19 pandemic, with 3-month follow-up (FUP) appointments conducted by phone and laboratory testing completed in community settings. Since November 2020, the clinic has adopted a mixed-service delivery model (Fig. 1), with services accessed through provider referral, self-referral, or referral from SHP staff. This model was intentionally retained post-pandemic to address several access barriers identified among priority populations, including transportation challenges and limited ability to take time off work. By combining phone-based follow-ups with at least one annual in-person visit, the model reduces travel requirements, which is particularly important in a mixed urban–rural catchment area, while maintaining clinical care. This approach is designed to improve equity in PrEP access by making the service more convenient and sustainable for clients with diverse needs.Fig. 1Mixed-service delivery model of the PrEP clinic. Legend. KFL&A PH – Kingston, Frontenac, Lennox, and Addington Public Health; STI – Sexually Transmitted Infection; PrEP- Pre-Exposure Prophylaxis; SMS – Short Message Service; Rx – Prescription Mixed-service delivery model of the PrEP clinic. Legend. KFL&A PH – Kingston, Frontenac, Lennox, and Addington Public Health; STI – Sexually Transmitted Infection; PrEP- Pre-Exposure Prophylaxis; SMS – Short Message Service; Rx – Prescription Appointments are scheduled and reminded via phone or through Short Message Service (SMS). Initial consultations, generally by phone, involve counselling and eligibility screening by nursing staff using the High Incidence Risk Index for Men who have Sex with Men (HIRI-MSM; cutoff ≥ 11), as per the national guidelines by Tan et al. [2], in conjunction with clinical judgment (Supplementary Table 2). Eligible clients are provided requisitions for baseline laboratory testing, which includes a fourth-generation HIV antibody/antigen test (with HIV rapid or viral load testing when indicated), syphilis serology, Polymerase Chain Reaction (PCR) detection of chlamydia and gonorrhea through urine and swabs at three anatomical sites (pharynx, urethra, anus), hepatitis A, B, and C serology, hepatitis C viral RNA PCR, and serum creatinine. Upon receipt of normal results, clients are scheduled for a physician appointment and prescribed either a continuous or intermittent oral PrEP regimen. FUP appointments occur at 30 days and every three months thereafter [2]. In accordance with national Canadian guidelines [2], HIV, syphilis, chlamydia, and gonorrhea testing is repeated every three months regardless of symptoms (Supplementary Table 3). FUPs are conducted by phone, with at least one annual in-person visit. Clients are responsible for accessing online requisitions and completing required testing before each visit. All encounters are documented in OSCAR, the clinic’s EMR system. Data source EMR data were retrospectively reviewed from the PrEP/MSM clinic calendar, extracted, and collated in a structured Microsoft Excel data table. Variable selection was informed by clinic staff and aligned with social disparities in Ontario HIV research.. Reach was described using sociodemographic, behavioral, and clinical characteristics available in the EMR, including: age, sex, place of residence (inside vs. outside the health unit’s geographical catchment of KFL&A), history of drug use (methamphetamine, amyl nitrate, and intravenous drug use), presence of a PCP, self-reported HIRI items (Supplemental – Table 2), prior use of post-exposure prophylaxis (PEP), history of STBBIs: syphilis, chlamydia, gonorrhea, hepatitis B, hepatitis C), and vaccination status for hepatitis A, hepatitis B, and human papillomavirus (HPV). Retention in care was also classified under Reach [25], measured by rates of initiation and disengagement. Rates of initiation were defined as the number of PrEP clients who were prescribed PrEP out of all PrEP clients who engaged in the clinic. Rates of disengagement were defined as intervals in months and was measured based on the time from initiation to the date reported in a clinical note of the EMR indicating a client is leaving the PrEP Clinics services. In contrast lost-to-follow-up was defined as a client who did not engage in care after three attempts of being contacted by clinic staff. Data on gender, sexual orientation, race, and socioeconomic status were not available in the EMR database. Effectiveness was defined as clinical outcomes guided by the HIV Prevention Cascade of Care Framework [15] and adapted to the PrEP Clinic’s mixed-service delivery model (Fig. 1). Variables extracted from the EMR to describe effectiveness included: 1) date of PrEP initiation and type of regimen started, 2) HIV and STI rates across four FUP periods, and 3) rates of adverse effects, including abdominal pain, diarrhea, enlarged lymph nodes, fatigue, headache, nausea, skin rash, other, and missing data [26]. The four FUP periods within our study were defined as a client’s first two FUP appointments (FUP-1 and FUP-2) and a client’s most recent two FUP appointments (FUP-3 and FUP-4). The STI and HIV positivity rates reported are calculated using the total number of clients with available test results at each follow-up as the denominator. Implementation-related indicators, such as rates of non-compliance and if counselling and risk reduction services were provided across four FUP periods. Risk reduction services are defined as either STBBI safe sex counseling, vaccine counseling, condom use guidance, and condom provision. Client characteristics were descriptively summarized with continuous variables presented as median (IQR) and categorical variables presented as frequencies. To identify predictors of PrEP initiation, Modified Poisson Regressions with robust standard estimates were used to estimate the risk ratios (RRs) and 95% Confidence Intervals (CIs) for unadjusted bivariate relationships of client characteristics against PrEP initiation status. All analyses were conducted using IBM SPSS Statistics Version 29.0.2.0 [20]. Data visualization was performed in Tableau Desktop (Version 2024.3.1). Ethics The research study was approved by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (HSERB) (TRAQ# DMED-2650–22), in accordance with the Canadian Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans – TCPS 2 and the Declaration of Helsinki. Consent to participate was waived for secondary use of retrospective chart review data and program evaluation purposes under TCPS 2, Article 3.7A and Article 3.7B. All secondary data were made unidentifiable by using unique participant identifier codes and retaining a corresponding master linking log (https://www.queensu.ca/vpr/ethics/guidelines-policies/waiver-consent). Results Describing reach Between November 2018 and December 2024, 141 clients engaged in the PrEP Clinic. The majority were male (97.2%; n = 137), with a median age of 37 years (IQR: 29–50). Most clients resided within the catchment area (74.5%; n = 105), and 57.4% (n = 81) reported having a PCP. A history of STBBIs was reported in 37.6% of clients, and among those with a history, chlamydia (24.1%; n = 34)) was the most common, followed by syphilis (19.9%; n = 28), and then gonorrhea (16.3%; n = 23). Vaccination history for hepatitis A and hepatitis B was evident among 70.9% (n = 100) and 75.9% (n = 107) of clients, respectively. Few clients reported intravenous drug use, and none reported being in a heterosexual serodiscordant relationship or using PEP more than once prior to their baseline appointment (Supplemental Table 3 and Table 1).Table 1Summary of client sociodemographic and clinical characteristics across initiation statusVariableOverall (n = 141)Initiated PrEP (n = 98)Did Not Initiate PrEP (n = 43)Relative Risk of PrEP initiation95% Confidence IntervalOverall Wald Chi Square Test (p-value)Sex Male97.2% (n = 137)98.0% (n = 96)95.3% (n = 41)N/AN/AX2 = 40.57 (p < 0.001) Transgender1.4% (n = 2)2.0% (n = 2)0.0% (n = 0)N/AN/A Female (ref)1.4% (n = 2)0.0% (n = 0)4.7% (n = 2)N/AN/AAge in years: median, (IQR)37 (29–50)37 (29–51)34 (28–45) < 180.0% (n = 0)0.0% (n = 0)0.0% (n = 0)-0X2 = 3.60 (p = 0.308) 18–2824.8% (n = 35)23.5% (n = 23)27.9% (n = 12)0.820.62–1.09 29–4035.5% (n = 50)33.7% (n = 33)39.5% (n = 17)0.830.64–1.06 41–4811.3% (n = 16)10.2% (n = 10)14.0% (n = 6)0.780.52–1.18 ≥49 (ref)28.4% (n = 40)32.7% (n = 32)18.6% (n = 8)1.00Residency Outside of KFL&A25.5% (n = 36)31.6% (n = 31)11.6% (n = 5)1.351.11–1.64*X2 = 9.09 (p = 0.003) Inside of KFL&A (ref)74.5% (n = 105)68.4% (n = 67)88.4% (n = 38)1.00Primary care provider status Yes57.4% (n = 81)59.2% (n = 58)53.5% (n = 23)1.040.81–1.32X2 = 0.64 (p = 0.725) No (ref)29.8% (n = 42)29.6% (n = 29)30.2% (n = 13)1.00 Missing12.8% (n = 18)11.2% (n = 11)16.3% (n = 7)0.890.56–0.85History of STBBIsSyphilis Yes19.9% (n = 28)18.4% (n = 18)23.3% (n = 10)0.910.67–1.23X2 = 0.40 (p = 0.529) No (ref)80.1% (n = 113)81.7% (n = 80)76.8% (n = 33)1.00Gonorrhea Yes16.3% (n = 23)16.3% (n = 16)16.3% (n = 7)1.000.75–1.35X2 = 0.0 (p = 0.994) No (ref)83.7% (n = 118)83.7% (n = 82)83.4% (n = 36)1.00Chlamydia Yes24.1% (n = 34)26.5% (n = 26)18.6% (n = 8)1.140.90–1.43X2 = 1.20 (p = 0.273) No (ref)75.9% (n = 107)73.5% (n = 72)81.4% (n = 35)1.00Hepatitis B Yes1.4% (n = 2)2.0% (n = 2)0.0% (n = 0)1.451.30–1.62X2 = 42.51 (p < 0.001) No (ref)98.6% (n = 139)98.0% (n = 96)100% (n = 43)1.00Hepatitis C Ever HCV Positive4.3% (n = 6)4.1% (n = 4)4.7% (n = 2)0.900.50–1.59X2 = 4.59 (p = 0.101) Never HCV Positive88.7% (n = 125)94.9% (n = 93)74.4% (n = 32)1.00 Missing7.1% (n = 10)1.0% (n = 1)20.9% (n = 9)0.130.021–0.87STBBI vaccination statusHepatitis A Vaccination Status Up to Date70.9% (n = 100)83.7% (n = 82)41.9% (n = 18)1.070.81–1.42X2 = 12.19 (p = 0.002) Not Immune (ref)12.1% (n = 17)3.1% (n = 3)9.3% (n = 4)1.00 Missing17.0% (n = 24)13.3% (n = 13)48.8% (n = 21)0.160.055–0.49*Hepatitis B Vaccination Status Up to Date75.9% (n = 107)83.7% (n = 82)58.1% (n = 25)1.0020.76–1.33X2 = 7.78 (p = 0.020) Not Immune (ref)12.1% (n = 17)13.3% (n = 13)9.3% (n = 4)1.00 Missing12.1% (n = 17)3.1% (n = 3)32.6% (n = 14)0.230.080–0.67*HPV Vaccination Status Vaccinated19.9% (n = 28)22.4% (n = 22)14.0% (n = 6)1.140.90–1.46X2 = 1.37 (p = 0.504) Eligible for OHIP coveragea but not vaccinated19.9% (n = 28)19.4% (n = 19)60.5% (n = 26)0.990.74–1.33 Ineligible for OHIP coverage and not vaccinated (ref)58.9% (n = 83)58.2% (n = 57)20.9% (n = 9)1.00 Missing1.4% (n = 2)0.0% (n = 0)4.7% (n = 2)0.00.0–0.0Relative risks, 95% confidence intervals, overall Wald Chi Square Test (p-value) were estimated through unadjusted bivariate analyses using a Modified Poission Regression with robust standard estimatedSTBBI Sexually transmitted and blood borne infection, HPV Human papillomavirus, HCV Hepatitis C virus, RR Relative Risks, CI Confidence Intervals*Statistical significanceaClients under 26 years old who identify as men who have sex with men (MSM) are eligible for complete coverage for the HPV series under the publicly funded Ontario Health Insurance Plan (OHIP) Table 1Summary of client sociodemographic and clinical characteristics across initiation statusVariableOverall (n = 141)Initiated PrEP (n = 98)Did Not Initiate PrEP (n = 43)Relative Risk of PrEP initiation95% Confidence IntervalOverall Wald Chi Square Test (p-value)Sex Male97.2% (n = 137)98.0% (n = 96)95.3% (n = 41)N/AN/AX2 = 40.57 (p < 0.001) Transgender1.4% (n = 2)2.0% (n = 2)0.0% (n = 0)N/AN/A Female (ref)1.4% (n = 2)0.0% (n = 0)4.7% (n = 2)N/AN/AAge in years: median, (IQR)37 (29–50)37 (29–51)34 (28–45) < 180.0% (n = 0)0.0% (n = 0)0.0% (n = 0)-0X2 = 3.60 (p = 0.308) 18–2824.8% (n = 35)23.5% (n = 23)27.9% (n = 12)0.820.62–1.09 29–4035.5% (n = 50)33.7% (n = 33)39.5% (n = 17)0.830.64–1.06 41–4811.3% (n = 16)10.2% (n = 10)14.0% (n = 6)0.780.52–1.18 ≥49 (ref)28.4% (n = 40)32.7% (n = 32)18.6% (n = 8)1.00Residency Outside of KFL&A25.5% (n = 36)31.6% (n = 31)11.6% (n = 5)1.351.11–1.64*X2 = 9.09 (p = 0.003) Inside of KFL&A (ref)74.5% (n = 105)68.4% (n = 67)88.4% (n = 38)1.00Primary care provider status Yes57.4% (n = 81)59.2% (n = 58)53.5% (n = 23)1.040.81–1.32X2 = 0.64 (p = 0.725) No (ref)29.8% (n = 42)29.6% (n = 29)30.2% (n = 13)1.00 Missing12.8% (n = 18)11.2% (n = 11)16.3% (n = 7)0.890.56–0.85History of STBBIsSyphilis Yes19.9% (n = 28)18.4% (n = 18)23.3% (n = 10)0.910.67–1.23X2 = 0.40 (p = 0.529) No (ref)80.1% (n = 113)81.7% (n = 80)76.8% (n = 33)1.00Gonorrhea Yes16.3% (n = 23)16.3% (n = 16)16.3% (n = 7)1.000.75–1.35X2 = 0.0 (p = 0.994) No (ref)83.7% (n = 118)83.7% (n = 82)83.4% (n = 36)1.00Chlamydia Yes24.1% (n = 34)26.5% (n = 26)18.6% (n = 8)1.140.90–1.43X2 = 1.20 (p = 0.273) No (ref)75.9% (n = 107)73.5% (n = 72)81.4% (n = 35)1.00Hepatitis B Yes1.4% (n = 2)2.0% (n = 2)0.0% (n = 0)1.451.30–1.62X2 = 42.51 (p < 0.001) No (ref)98.6% (n = 139)98.0% (n = 96)100% (n = 43)1.00Hepatitis C Ever HCV Positive4.3% (n = 6)4.1% (n = 4)4.7% (n = 2)0.900.50–1.59X2 = 4.59 (p = 0.101) Never HCV Positive88.7% (n = 125)94.9% (n = 93)74.4% (n = 32)1.00 Missing7.1% (n = 10)1.0% (n = 1)20.9% (n = 9)0.130.021–0.87STBBI vaccination statusHepatitis A Vaccination Status Up to Date70.9% (n = 100)83.7% (n = 82)41.9% (n = 18)1.070.81–1.42X2 = 12.19 (p = 0.002) Not Immune (ref)12.1% (n = 17)3.1% (n = 3)9.3% (n = 4)1.00 Missing17.0% (n = 24)13.3% (n = 13)48.8% (n = 21)0.160.055–0.49*Hepatitis B Vaccination Status Up to Date75.9% (n = 107)83.7% (n = 82)58.1% (n = 25)1.0020.76–1.33X2 = 7.78 (p = 0.020) Not Immune (ref)12.1% (n = 17)13.3% (n = 13)9.3% (n = 4)1.00 Missing12.1% (n = 17)3.1% (n = 3)32.6% (n = 14)0.230.080–0.67*HPV Vaccination Status Vaccinated19.9% (n = 28)22.4% (n = 22)14.0% (n = 6)1.140.90–1.46X2 = 1.37 (p = 0.504) Eligible for OHIP coveragea but not vaccinated19.9% (n = 28)19.4% (n = 19)60.5% (n = 26)0.990.74–1.33 Ineligible for OHIP coverage and not vaccinated (ref)58.9% (n = 83)58.2% (n = 57)20.9% (n = 9)1.00 Missing1.4% (n = 2)0.0% (n = 0)4.7% (n = 2)0.00.0–0.0Relative risks, 95% confidence intervals, overall Wald Chi Square Test (p-value) were estimated through unadjusted bivariate analyses using a Modified Poission Regression with robust standard estimatedSTBBI Sexually transmitted and blood borne infection, HPV Human papillomavirus, HCV Hepatitis C virus, RR Relative Risks, CI Confidence Intervals*Statistical significanceaClients under 26 years old who identify as men who have sex with men (MSM) are eligible for complete coverage for the HPV series under the publicly funded Ontario Health Insurance Plan (OHIP) Summary of client sociodemographic and clinical characteristics across initiation status Relative risks, 95% confidence intervals, overall Wald Chi Square Test (p-value) were estimated through unadjusted bivariate analyses using a Modified Poission Regression with robust standard estimated STBBI Sexually transmitted and blood borne infection, HPV Human papillomavirus, HCV Hepatitis C virus, RR Relative Risks, CI Confidence Intervals *Statistical significance aClients under 26 years old who identify as men who have sex with men (MSM) are eligible for complete coverage for the HPV series under the publicly funded Ontario Health Insurance Plan (OHIP) Living outside of the catchment area (RR = 1.35, 95% CI: 1.11–1.64) and having a history of hepatitis B (RR = 1.45, 95% CI: 1.30–1.62) were positively associated with PrEP initiation. Missing data on PCP attachment (RR = 0.89, 95% CI: 0.56–0.85), hepatitis A vaccination history (RR = 0.16, 95% CI: 0.06–0.49), and a hepatitis B vaccination history (RR = 0.23, 95% CI: 0.08–0.67) were negatively associated with PrEP initiation. Other sociodemographic factors, such as HPV vaccination status and history of other STBBIs, were not associated with initiation (Table 2).Table 2Summary of the HIRI-MSM items based on initiation statusHIRI VariableOverall (n = 141)Initiated PrEP(n = 98)Did not Initiate PrEP(n = 43)Relative Risk of PrEP Initiation95% Confidence IntervalOverall Wald Chi Square Test (p-value)Number of male sexual partners in the last 6 months > 1018.4% (n = 26)19.4% (n = 19)16.3% (n = 7)0.990.75–1.31X2 = 5.98 (p = 0.112) 6–1021.3% (n = 30)24.5% (n = 24)6.0% (n = 14)1.070.86–1.38 0–5 (ref)40.4% (n = 57)42.9% (n = 42)34.9% (n = 15)1 Missing19.9% (n = 28)13.3% (n = 13)34.9% (n = 15)0.630.41–0.97Number of receptive anal sex events with a man without a condom 1 or more times51.1% (n = 72)59.2% (n = 58)32.6% (n = 14)1.220.96–1.57X2 = 8.44 (p = 0.015) None (ref)29.1% (n = 41)27.6% (n = 27)32.6% (n = 14)1 Missing19.9% (n = 28)13.3% (n = 13)34.9% (n = 15)0.710.45–1.11Number of male HIV-positive sex partners > 1 positive partner2.1% (n = 3)3.1% (n = 3)0.0% (n = 0)1.331.18–1.49X2 = 41.06 (p = < 0.001) 1 positive partner10.6% (n = 15)11.2% (n = 11)9.3% (n = 4)0.970.70–1.35 < 1 positive partner (ref)66.0% (n = 93)71.4% (n = 70)53.5% (n = 23)1 Missing21.3% (n = 30)14.3% (n = 14)37.2% (n = 16)0.620.42–0.93Number of insertive anal sex events without a condom and with an HIV positive partner 5 or more times3.5% (n = 5)4.1% (n = 4)2.3% (n = 1)1.060.67–1.66X2 = 6.20 (p = 0.045) 0–4 times (ref)75.9% (n = 107)82.5% (n = 81)60.5% (n = 26)1 Missing20.6% (n = 29)13.3% (n = 13)37.2% (n = 16)0.590.39–0.90Methamphetamine use Yes2.1% (n = 3)2.0% (n = 2)2.3% (n = 1)0.890.40–2.00X2 = 4.56 (p = 0.103) No (ref)78.7% (n = 111)84.7% (n = 83)65.1% (n = 28)1 Missing19.1% (n = 27)13.3% (n = 13)32.6% (n = 14)0.640.43–0.97Amyl nitrate use Yes18.4% (n = 26)19.4% (n = 19)16.3% (n = 7)0.960.74—1.25X2 = 5.37 (p = 0.068) No (ref)61.7% (n = 87)67.3% (n = 66)48.8% (n = 21)1 Missing19.9% (n = 28)13.3% (n = 13)34.9% (n = 15)0.610.40–0.93Relative risks, 95% confidence intervals, overall Wald Chi Square Test (p-value) were estimated through unadjusted bivariate analyses using a Modified Poission Regression with robust standard estimatedCI Confidence Intervals, Ref Reference, RR Relative Risks, PrEP Pre-Exposure Prophylaxis Table 2Summary of the HIRI-MSM items based on initiation statusHIRI VariableOverall (n = 141)Initiated PrEP(n = 98)Did not Initiate PrEP(n = 43)Relative Risk of PrEP Initiation95% Confidence IntervalOverall Wald Chi Square Test (p-value)Number of male sexual partners in the last 6 months > 1018.4% (n = 26)19.4% (n = 19)16.3% (n = 7)0.990.75–1.31X2 = 5.98 (p = 0.112) 6–1021.3% (n = 30)24.5% (n = 24)6.0% (n = 14)1.070.86–1.38 0–5 (ref)40.4% (n = 57)42.9% (n = 42)34.9% (n = 15)1 Missing19.9% (n = 28)13.3% (n = 13)34.9% (n = 15)0.630.41–0.97Number of receptive anal sex events with a man without a condom 1 or more times51.1% (n = 72)59.2% (n = 58)32.6% (n = 14)1.220.96–1.57X2 = 8.44 (p = 0.015) None (ref)29.1% (n = 41)27.6% (n = 27)32.6% (n = 14)1 Missing19.9% (n = 28)13.3% (n = 13)34.9% (n = 15)0.710.45–1.11Number of male HIV-positive sex partners > 1 positive partner2.1% (n = 3)3.1% (n = 3)0.0% (n = 0)1.331.18–1.49X2 = 41.06 (p = < 0.001) 1 positive partner10.6% (n = 15)11.2% (n = 11)9.3% (n = 4)0.970.70–1.35 < 1 positive partner (ref)66.0% (n = 93)71.4% (n = 70)53.5% (n = 23)1 Missing21.3% (n = 30)14.3% (n = 14)37.2% (n = 16)0.620.42–0.93Number of insertive anal sex events without a condom and with an HIV positive partner 5 or more times3.5% (n = 5)4.1% (n = 4)2.3% (n = 1)1.060.67–1.66X2 = 6.20 (p = 0.045) 0–4 times (ref)75.9% (n = 107)82.5% (n = 81)60.5% (n = 26)1 Missing20.6% (n = 29)13.3% (n = 13)37.2% (n = 16)0.590.39–0.90Methamphetamine use Yes2.1% (n = 3)2.0% (n = 2)2.3% (n = 1)0.890.40–2.00X2 = 4.56 (p = 0.103) No (ref)78.7% (n = 111)84.7% (n = 83)65.1% (n = 28)1 Missing19.1% (n = 27)13.3% (n = 13)32.6% (n = 14)0.640.43–0.97Amyl nitrate use Yes18.4% (n = 26)19.4% (n = 19)16.3% (n = 7)0.960.74—1.25X2 = 5.37 (p = 0.068) No (ref)61.7% (n = 87)67.3% (n = 66)48.8% (n = 21)1 Missing19.9% (n = 28)13.3% (n = 13)34.9% (n = 15)0.610.40–0.93Relative risks, 95% confidence intervals, overall Wald Chi Square Test (p-value) were estimated through unadjusted bivariate analyses using a Modified Poission Regression with robust standard estimatedCI Confidence Intervals, Ref Reference, RR Relative Risks, PrEP Pre-Exposure Prophylaxis Summary of the HIRI-MSM items based on initiation status Relative risks, 95% confidence intervals, overall Wald Chi Square Test (p-value) were estimated through unadjusted bivariate analyses using a Modified Poission Regression with robust standard estimated CI Confidence Intervals, Ref Reference, RR Relative Risks, PrEP Pre-Exposure Prophylaxis Most clients (40.4%) reported having 0–5 male sexual partners in the six months prior to intake (Table 2). Over half reported receptive anal sex without a condom at least once (51.1%; n = 72), and 66.0% (n = 93) had no known HIV-positive male partners. The majority (75.9%; n = 107) reported limited insertive anal sex without a condom with an HIV-positive partner. Methamphetamine use was rare (< 5%), while 18.4% had used amyl nitrate. Among the 98 clients who initiated PrEP, most clients reported engaging in moderate-high risk factors in only two out of the seven items HIRI age and the number of receptive anal sex events with a man without a condom, while the other categories showed most clients engaging in low-risk behaviours (Fig. 2). Data were missing for 13–14% of clients across categories. Having more than one HIV-positive partner increased the likelihood of PrEP initiation (RR = 1.33, 95% CI: 1.18–1.49), however no other category on the HIRI was associated with PrEP initiation, as seen in Table 2. Missing data on the number of male sexual partners (RR = 0.63, 95% CI: 0.41–0.97), insertive anal sex with HIV-positive partners (RR = 0.59, 95% CI: 0.39–0.90), and amyl nitrate use (RR = 0.61, 95% CI: 0.40–0.93) were associated with a reduced likelihood of initiation. reduced likelihood of initiation.Fig. 2Distribution of High Incidence Risk Index for Men who have Sex with Men (HIRI-MSM) items stratified by risk level among clients who initiated PrEP (n = 98) Distribution of High Incidence Risk Index for Men who have Sex with Men (HIRI-MSM) items stratified by risk level among clients who initiated PrEP (n = 98) Reach: retention The median engagement duration was eight months (IQR: 3–21). Among initiators, 54.1% (n = 53) disengaged from care, and 7.6% (n = 4) were lost to follow-up. Disengagement peaked at 2–3 months (24.0%) and 12–23 months (24.0%), with the lowest disengagement during months 7–9 (4.0%) (Fig. 3). Among those who disengaged, the most common reasons were transferring care (24.5%), primarily to a PCP (n = 10), relocating outside the catchment area (18.9%), and changes in sexual activity (17.0%). Few clients cited adverse effects or lack of insurance as reasons for disengagement. Disengagement reasons were missing for 20.8% (n = 11) of clients. While these findings reflect implementation processes, we included them to help explain retention patterns and strengthen interpretation of the Reach and Effectiveness outcomes.Fig. 3Disengagement rates over intervals of time attending the PrEP Clinic. Legend. PrEP- Pre-exposure prophylaxis Disengagement rates over intervals of time attending the PrEP Clinic. Legend. PrEP- Pre-exposure prophylaxis Effectiveness: STI and HIV outcomes Among those who initiated PrEP (n = 98), 70.4% (n = 69) were prescribed a continuous regimen. Across four follow-up visits, no clients tested positive for HIV, confirming the effectiveness of PrEP in preventing seroconversion (Fig. 4). The proportion of clients with documented HIV-negative status remained high, ranging from 86.49% (n = 64) at FUP-4 to 98.59% (n = 70) at FUP-2. Missing HIV status data was highest at FUP-4 (13.51%, n = 10) (Supplemental Table 4).Fig. 4Rates of STBBIs across the four follow-up periods among PrEP. Legend. STBBI—Sexually transmitted and blood borne infection; Human immunodeficiency virus (HIV) Rates of STBBIs across the four follow-up periods among PrEP. Legend. STBBI—Sexually transmitted and blood borne infection; Human immunodeficiency virus (HIV) Syphilis seropositivity remained stable across follow-ups (range: 8–11%). Confirmed negative results peaked at FUP-2 (84.5%) but declined slightly by FUP-4 (70.3%). Missing syphilis results were high at FUP-1 (58.6%), as seen in Supplemental—Table 4. Chlamydia and gonorrhea positivity remained low throughout. At most follow-ups, positivity was < 5%. The proportion of negative test results improved across time points, while missingness decreased substantially after FUP-1. These findings suggest improved fidelity of STI testing among engaged clients over time (Fig. 4). Effectiveness: adverse effects and adherence Adverse effects were most frequently reported at FUP-1 (36.8%), declining to < 6% at subsequent follow-ups (Table 3). Common symptoms included nausea, diarrhea, and fatigue. Non-compliance, defined as missing pills, declined from 23.0% at FUP-1 to 5.4% at FUP-4. By FUP-4, 93.2% of clients reported adherence to PrEP treatment as prescribed. Adherence counseling was provided to 26.4% of clients at FUP-1 and peaked at FUP-2 (33.3%), then declined. Risk reduction services were most frequently documented at FUP-2 (50.7%), aligning with elevated non-compliance and STI rates.Table 3Summary of rates estimating adherence over four follow-up appointmentsCharacteristicFollow-Up 1 (n = 87)Follow-Up 2 (n = 71)Follow-Up 3 (n = 61)Follow-Up 4 (n = 74)Adverse effects Yes36.78% (n = 32)5.63% (n = 4)3.28% (n = 2)2.70% (n = 2) Abdominal pain3.13% (n = 1)50.0% (n = 2)0.0% (n = 0)0.0% (n = 0) Diarrhea15.63% (n = 5)25.0% (n = 1)0.0% (n = 0)0.0% (n = 0) Enlarged lymph nodes3.13% (n = 1)0.0% (n = 0)0.0% (n = 0)0.0% (n = 0) Fatigue9.34% (n = 3)0.0% (n = 0)0.0% (n = 0)50.0% (n = 1) Headache6.25% (n = 2)0.0% (n = 0)0.0% (n = 0)0.0% (n = 0) Nausea21.86% (n = 7)25.0% (n = 1)0.0% (n = 0)50.0% (n = 1) Skin rash3.13% (n = 1)0.0% (n = 0)0.0% (n = 0)0.0% (n = 0) Other37.5% (n = 12)0.0% (n = 0)50.0% (n = 1)0.0% (n = 0) Missing0.0% (n = 0)0.0% (n = 0)50.0% (n = 1)0.0% (n = 0)Non-compliance Yes22.99% (n = 20)18.31% (n = 13)10.91% (n = 6)5.41% (n = 4) No98.85% (n = 65)80.28% (n = 57)90.16% (n = 55)93.24% (n = 69) Missing2.30% (n = 2)1.41% (n = 1)0.0% (n = 0)1.35% (n = 1)Adherence counselling provided Yes26.44% (n = 23)33.33% (n = 18)8.20% (n = 5)8.11% (n = 6) No67.82% (n = 59)76.06% (n = 54)91.80% (n = 56)90.54% (n = 67) Missing5.75% (n = 5)0.0% (n = 0)0.0% (n = 0)1.35% (n = 1)Risk reduction provided Yes35.63% (n = 31)50.70% (n = 36)19.67% (n = 12)18.92% (n = 14) No58.62% (n = 51)49.30% (n = 35)80.33% (n = 49)79.73% (n = 59) Missing5.75% (n = 5)0.0% (n = 0)0.0% (n = 0)1.35% (n = 1) Table 3Summary of rates estimating adherence over four follow-up appointmentsCharacteristicFollow-Up 1 (n = 87)Follow-Up 2 (n = 71)Follow-Up 3 (n = 61)Follow-Up 4 (n = 74)Adverse effects Yes36.78% (n = 32)5.63% (n = 4)3.28% (n = 2)2.70% (n = 2) Abdominal pain3.13% (n = 1)50.0% (n = 2)0.0% (n = 0)0.0% (n = 0) Diarrhea15.63% (n = 5)25.0% (n = 1)0.0% (n = 0)0.0% (n = 0) Enlarged lymph nodes3.13% (n = 1)0.0% (n = 0)0.0% (n = 0)0.0% (n = 0) Fatigue9.34% (n = 3)0.0% (n = 0)0.0% (n = 0)50.0% (n = 1) Headache6.25% (n = 2)0.0% (n = 0)0.0% (n = 0)0.0% (n = 0) Nausea21.86% (n = 7)25.0% (n = 1)0.0% (n = 0)50.0% (n = 1) Skin rash3.13% (n = 1)0.0% (n = 0)0.0% (n = 0)0.0% (n = 0) Other37.5% (n = 12)0.0% (n = 0)50.0% (n = 1)0.0% (n = 0) Missing0.0% (n = 0)0.0% (n = 0)50.0% (n = 1)0.0% (n = 0)Non-compliance Yes22.99% (n = 20)18.31% (n = 13)10.91% (n = 6)5.41% (n = 4) No98.85% (n = 65)80.28% (n = 57)90.16% (n = 55)93.24% (n = 69) Missing2.30% (n = 2)1.41% (n = 1)0.0% (n = 0)1.35% (n = 1)Adherence counselling provided Yes26.44% (n = 23)33.33% (n = 18)8.20% (n = 5)8.11% (n = 6) No67.82% (n = 59)76.06% (n = 54)91.80% (n = 56)90.54% (n = 67) Missing5.75% (n = 5)0.0% (n = 0)0.0% (n = 0)1.35% (n = 1)Risk reduction provided Yes35.63% (n = 31)50.70% (n = 36)19.67% (n = 12)18.92% (n = 14) No58.62% (n = 51)49.30% (n = 35)80.33% (n = 49)79.73% (n = 59) Missing5.75% (n = 5)0.0% (n = 0)0.0% (n = 0)1.35% (n = 1) Summary of rates estimating adherence over four follow-up appointments Discussion This evaluation demonstrates that a hybrid PrEP delivery model, combining phone and in-person services within a mid-sized public health unit can effectively reach at-risk gbMSM clients in suburban and rural settings, facilitate PrEP initiation, and sustain adherence and retention. Among clients who expressed interest, 70% initiated PrEP, no HIV seroconversions occurred, and the clinic achieved a notably low rate of lost-to-follow-up (7.6%). While overall disengagement from the program was moderate (53%), many clients remained adherent, and the clinic responded effectively by providing risk-reduction counselling and facilitating transfers of care to PCPs upon disengagement, highlighting continuity of care. Our evaluation adds to the limited Canadian literature describing PrEP users by focusing on a mixed suburban and rural region of Southeastern Ontario, whereas existing evaluations have primarily been conducted in major metropolitan centres across Canada, such as Ottawa, Toronto, Vancouver, and Montréal. The demographic profile of our cohort is broadly consistent with PrEP cohorts in major metropolitan cities. The Ottawa PrEP-RN cohort enrolled 89 clients over a two-year period, all male with a majority identifying as gay or bisexual men, predominately over the age of 25 [9]. In comparison, a Toronto implementation study prescribed PrEP to 244 of 275 (88.7%) men who attended appointments over two years, with a median age of 31 years [7]. The Montréal-based L’Actuel PrEP cohort, the largest in Canada, included 2,156 clients consulting for PrEP over five years, of whom 1,551 initiated, with a median age of 35 years, 98% cis-male, and 97% identifying as homosexual or bisexual [27]. Taken together, our mixed suburban and rural cohort of 141 clients over six years, predominantly males (97.2%) who identify as gbMSM, with a median age of 37 years, is broadly consistent with these metropolitan cohorts in terms of sex, sexual orientation, and age. The smaller population size over the study period is likely reflective of the clinic’s suburban and rural catchment area, where population density is lower and PrEP awareness and accessibility may differ from large urban centres, further underscoring the importance of evaluating PrEP delivery models outside major metropolitan contexts. Our initiation and retention rates are comparable to larger scale delivery models located in urban centres in Canada, such as Ottawa’s PrEP-RN program (69%), and surpasses national estimates of PrEP uptake among gbMSM [9, 28]. Alike to other PrEP service delivery models, no clients who initiated PrEP were later diagnosed with HIV [9, 28], a key finding of the study, demonstrating real-world effectiveness of this mixed-service delivery model. Importantly, these findings highlight the feasibility of delivering PrEP through a hybrid in-person and telephone clinic, which supports high adherence and retention while removing common barriers such as travel distance or scheduling constraints, particularly for clients in suburban and rural settings. The relatively low number of STIs detected in our cohort overtime may reflect differences in baseline risk profiles between suburban/rural and metropolitan populations. In Ottawa’s nurse-led PrEP-RN cohort, 21% of clients were diagnosed with an STI during follow-up, whereas our study observed syphilis seropositivity of 8–11% and chlamydia/gonorrhea positivity below 5% across follow-up periods [9]. While, STI positivity remained low and stable across FUPs, interpretation is limited by substantial missing data, particularly at FUP-1. While missingness is partially attributable to the clinic’s testing schedule (Supplemental Table 2), this also reflects variable fidelity early in implementation. The decline in missingness over time suggests improved adherence to testing protocols and greater client engagement. Compared to the Montréal-based L’Actuel PrEP cohort [27], which reported STI rates utilizing the same laboratory measures, Greenwald et al. reported increased STI incidence post-initiation after controlling for increased testing frequency, our lower rates may reflect differences in baseline risk profiles and sexual network dynamics between suburban/rural and urban populations, as seen in the Montréal-based L’Actuel PrEP cohort. Although our disengagement rate was higher than in other Canadian models [9], not all instances of disengagement indicated implementation challenges. A substantial number of clients disengaged after long-term engagement (40% after 12 months), with many clients transferring care to their PCPs for ongoing PrEP management, which the clinic actively supported through consultation and resource-sharing directly with providers. These efforts highlight a key strength of the PrEP Clinic, as it enables the seamless and sustainable continuity of care across settings. Notably, differences in PrEP uptake among our clinic compared to other PrEP service deliver models may reflect differences in referral pathways and population characteristics, as many of our clients self-elect, likely entering the program with higher baseline awareness, fewer structural barriers, and greater motivation to accessing PrEP. Supporting this, clients residing outside our clinic’s catchment region were significantly more likely to initiate PrEP, suggesting that those traveling farther may have been more proactive, knowledgeable, and motivated to engage in HIV prevention services. Together, these findings suggest that our hybrid, public-health base model is both accessible and can sustain meaningful continuity of care, offering strong implementation indications across the full PrEP cascade of care, particularly in suburban and rural settings where inequities persist. Despite PrEP’s proven efficacy, uptake remains disproportionately concentrated among white, cisgender gay men in urban areas of Canada [5, 29]. This is reflected in national surveillance data from nine provinces which indicate that 98% of PrEP users are male, highlighting the high uptake among gbMSM [5]. To better evaluate PrEP use relative to HIV risk, the “PrEP-to-need ratio” has been developed, defined as the number of individuals on PrEP per new HIV diagnosis [16]. A higher ratio indicates that PrEP use is more closely aligned with epidemiological need [16]. Within Ontario, substantial geographic disparities exist: the Eastern Ontario health region, where the PrEP Clinic is located, has a PrEP-to-need ratio of 15.5 which is distinctly lower than Ottawa (37.9) and Toronto (31.2), further underscoring geographical inequities in access relative to HIV risk [16]. These disparities stem from individual and structural-level barriers, such as stigma, limited provider availability, affordability, as seen in particularly in Ontario where PrEP is not universally covered [29]. The PrEP Clinic directly addresses these challenges through a hybrid self-referral approach that combines in-person and telehealth services and effectively reduces common barriers to access including referral requirements, limited operating hours, and geographic proximity, while preserving discretion and privacy. Furthermore, the clinic does not require provincial health coverage through OHIP to attend a consultation. This flexible low-barrier approach parallels findings from Iowa’s TelePrEP program and Denver’s Telehealth PrEP services, both of which demonstrated that decentralized, online-enabled care can sustain client engagement and retention, even in geographically dispersed or resource-limited settings [30, 31]. Although the clinic serves predominantly gbMSM, the small proportion of women reflects both regional HIV epidemiology and the clinic’s historical focus on this population [32]. Women at elevated risk include Indigenous women in Northern Ontario, African, Caribbean, and Black women, and transgender women, who report higher HIV incidence. Future efforts could consider strategies to expand reach of culturally relevant interventions to women who are currently underrepresented in PrEP service [16, 33]. Although our study lacked key sociodemographic variables such as race, sexual orientation, and socioeconomic status, and most of our clients are gbMSM, the model is well-positioned for expansion. Through tailored outreach and partnership with community-based organization, public health-led models can help address persistent structural inequities in HIV prevention among underserved populations. Strengths and limitations This study possesses many strengths that further support the validity of these findings. This is the first study, to our knowledge, to evaluate the implementation of a PrEP clinic outside a major metropolitan city in Canada, highlighting a regional success story for suburban and rural located public health units. Findings from this study provide critical evidence to inform future expansion efforts in suburban and rural settings and among public health. Furthermore, this study leveraged a participatory-based research approach by prioritizing consultation and regular reflexive feedback with the PrEP Clinic staff throughout the research process, ensuring the study design, interpretation of findings, and knowledge translation were relevant to key stakeholders. Finally, the sample size included in data analysis is relatively large (n = 141) for a mid-sized PHU and reflects a relatively diverse population based on age and risk level. This study has several potential limitations. Missing data was a significant limitation present in the study. Lack of online documentation for some variables, such as the HIRI-MSM items, may be attributed to either documentation not being transferred and uploaded from the paper copy to the EMR database or incompletion. Furthermore, data on gender, sexual orientation, race, and socioeconomic status were not available in the EMR database as these variables are currently not systematically recorded at client encounters. Overall, missingness limited the ability to fully characterize the sample and conduct stratified analyses with sufficient power. Furthermore, missing data were associated with PrEP initiation status among some key characteristics, highlighting a clinically relevant gap in charting processes. In addition, inter-client variability in charting procedures were also apparent when the research team was collecting data on date of disengagement. Time constraints associated with the project prevented an inter-reliability check to minimize the effects of the high inter-client variability, which also may have introduced measurement error. Finally, while the HIRI tool is widely used, its limitations are increasingly recognized. The initial validation cohort underrepresented equity-deserving groups [34], and the tool relies on self-reported data which may be subjected to measurement error or social desirability bias. Furthermore, the HIRI was originally designed to screen MSM, limiting the language and clinical utility to sexual relationships among gbMSM. While the PrEP Clinic combines with the use of the HIRI with clinical judgement when determining client eligibility, it is suggested that this lack of inclusive language embedded in the tool may be limiting the clinic’s ability to reach other high-priority populations currently underrepresented. Future directions There is an evident gap in representation of high-priority populations at the PrEP Clinic. Currently, the PrEP Clinic does not have any outreach or marketing strategies to raise awareness among the public thus, the only clients accessing the clinic are those with prior knowledge on PrEP and/or the clinic’s existence, or those who are referred. To improve reach, it is recommended that PrEP clinics implement outreach strategies towards underrepresented priority populations. This should include promoting tailored marketing campaigns through social media platforms, such as Instagram and Grindr, and leveraging pre-existing partnerships with community-based organizations as a point of promotion and contact, as these organizations are places clients may already frequent and trust. Based on findings from this evaluation and gaps in the literature, there is a need to increase the quantity and quality of data describing PrEP cohorts outside of metropolitan areas in Canada. To improve clinic implementation strategies in data quality, it is recommended that clinics develop procedures to standardize charting and optimize data extraction for future evaluations. In addition, it is recommended that public health provide better support, education, and training for PrEP providers to collect data surrounding health equity objectives, such as race, gender, and sexual orientation, to close gaps in data missingness [18]. Future research should also examine the representativeness and geographic reach of PrEP clients, for example by geocoding patient addresses to explore distance traveled and rural versus urban patterns of access. This would be particularly relevant for mixed telephone–in person PrEP service models, which are designed to reduce geographic barriers and may help extend access to more rural and remote populations. Finally, future studies should focus on expanding and refining the implementation and evaluations of public health–led models, like ours in other suburban and rural contexts. In particular, further work is needed to understand how this model can be adapted to better reach populations that remain underrepresented in PrEP care, including Indigenous communities and other equity-deserving groups. Evaluations that incorporate client and provider perspectives within these settings can help identify individual and delivery-level facilitators and barriers to implementation. Additionally, comparative studies of alternative models of care, such as those led by nurses, pharmacists, or community-based organizations, may further inform how PrEP can be scaled equitably beyond physician- or hospital-based clinics. Conclusion This evaluation contributes to growing evidence that mixed-service PrEP delivery models embedded within public health settings are both effective and adaptable. Our findings demonstrate that such models can achieve high initiation rates, low loss to follow-up, and sustained continuity of care, even in suburban and rural regions where structural barriers and low uptake are prevalent. As HIV incidence continues to rise in Canada, scaling, adapting, and diversifying PrEP service delivery models will be critical to expanding equitable access. Public health units are well-positioned to lead this effort by leveraging their existing infrastructure and expertise to deliver responsive, community-centered HIV prevention services. Supplementary Information Supplementary Material 1: Supplemental - Table 2. High Incidence Risk Index for Men who have Sex with Men (HIRI-MSM) Assessment Form with Risk Stratification. Supplemental - Table 3. Laboratory Testing Schedule. Supplemental - Table 4. Summary of Heterosexual Serodiscordant and Shared Intravenous Drug Use Risk Assessment. Supplemental - Table 5. Summary of Rates Estimating Effectiveness over Four Follow-up Appointments Supplementary Material 1: Supplemental - Table 2. High Incidence Risk Index for Men who have Sex with Men (HIRI-MSM) Assessment Form with Risk Stratification. Supplemental - Table 3. Laboratory Testing Schedule. Supplemental - Table 4. Summary of Heterosexual Serodiscordant and Shared Intravenous Drug Use Risk Assessment. Supplemental - Table 5. Summary of Rates Estimating Effectiveness over Four Follow-up Appointments